Figure 1.
Failure-free survival of 90 eligible patients with stages II to IV follicular non-Hodgkin lymphoma treated with 6 cycles of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab.
Failure-free survival of 90 eligible patients with stages II to IV follicular non-Hodgkin lymphoma treated with 6 cycles of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab.
